Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

byBenzinga Newsdesk

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

Analyst Ratings

Where TPI Composites Stands With Analysts

By Benzinga Insights

May 23, 9:00 AM

Analysts have provided the following ratings for TPI Composites (NASDAQ:TPIC) within the last quarter: Bullish Somewhat Bullish Indifferent…

TPIC

What Does Okta’s Debt Look Like?

By Benzinga Insights

January 9, 2:16 PM

Shares of Okta Inc. (NASDAQ:OKTA) increased by 35.11% in the past three months. Before having a look at the importance of debt, let's look at how much debt Okta has.

OKTA

News

SEC’s Division Of Corporation Finance Office Of Technology Sends Letter To Twitter’s Parag Agrawal; SEC To Agrawal, In Letter Dated June 15, Requests Disclosing Methodology Used In Calculating MDAU Figures And Underlying Judgements & Assumptions Used

By Benzinga Newsdesk

August 24, 10:20 AM

- Reuters

TWTR

Analyst Ratings

Analyst Expectations For Intl Flavors & Fragrances’s Future

By Benzinga Insights

January 11, 4:01 PM

Ratings for Intl Flavors & Fragrances (NYSE:IFF) were provided by 7 analysts in the past three months, showcasing…

IFF

Oppenheimer Downgrades Fate Therapeutics to Perform

Related Posts

Where TPI Composites Stands With Analysts

What Does Okta’s Debt Look Like?

SEC’s Division Of Corporation Finance Office Of Technology Sends Letter To Twitter’s Parag Agrawal; SEC To Agrawal, In Letter Dated June 15, Requests Disclosing Methodology Used In Calculating MDAU Figures And Underlying Judgements & Assumptions Used

Analyst Expectations For Intl Flavors & Fragrances’s Future